Cupid Ltd Q1 FY27 Revenue to Exceed ₹150 Cr; FY27 Outlook Raised to ₹660+ Cr
Cupid Limited projects Q1 FY27 revenue exceeding ₹150 Cr, one of its strongest quarterly performances, prompting management to raise FY27 revenue guidance by a minimum of 10% to ₹660+ Cr from ₹600 Cr. Growth is driven by a long-term supply agreement with PFSCM Netherlands, strong order visibility across global markets, and expanding MC, FC, and lubricant portfolios. The Company also plans to operationalise its new Palava manufacturing facility in the coming quarter.

*this image is generated using AI for illustrative purposes only.
Cupid Limited is on track to deliver revenue exceeding ₹150 Cr in the first quarter of FY27, marking one of the strongest quarterly performances in the Company's history. Driven by this exceptional start to the financial year and improved visibility across international and domestic markets, the management has revised its FY27 revenue outlook upward by a minimum of 10%. The revised guidance targets ₹660+ Cr, up from the previous estimate of ₹600 Cr.
Revised Revenue Outlook
The updated financial projections reflect growing confidence in the Company's diversified business model, expanding global opportunity pipeline, and increasing operating scale across multiple business verticals.
| Financial Metric: | Details |
|---|---|
| Q1 FY27 Revenue Projection: | ₹150+ Cr |
| Previous FY27 Guidance: | ₹600 Cr |
| Revised FY27 Guidance: | ₹660+ Cr |
| Guidance Revision: | Minimum 10% upward |
Key Growth Drivers
The revised FY27 revenue outlook is supported by multiple long-term growth drivers, including expanding opportunities across international B2B healthcare markets. This is driven by rising demand from institutional buyers, private sector customers, and government procurement programmes. The Company has successfully commenced its long-term supply agreement with Partnership for Supply Chain Management (PFSCM), Netherlands, strengthening its position in global healthcare procurement.
Strong order visibility exists across private markets, institutional business, and international tenders spanning multiple geographies. Continued growth in the Male Condom (MC) and Female Condom (FC) businesses is supported by enhanced manufacturing capabilities, customer acquisition, and wider market reach over the past twelve months. Additionally, growing opportunities in the lubricant portfolio are backed by increasing acceptance across both institutional and consumer channels.
Future Prospects
Management sees significant long-term potential in the consumer business as the Company continues to build a mainstream personal care and wellness brand. Its presence is expanding across modern trade, organised retail, and pharmacy networks across Bharat. Ongoing capacity expansion, operational efficiencies, and backward integration initiatives are expected to support sustained growth while improving profitability. The Company is also actively participating in IVD kits and menstrual cup tenders across multiple states.
Aditya Kumar Halwasiya, Chairman & Managing Director, Cupid Limited, highlighted that the strong start to FY27 reflects the transformation the Company has undergone. He noted that the strategic relationship with PFSCM has commenced on an encouraging note. Furthermore, the Company plans to operationalise its new Palava manufacturing facility in the coming quarter to further strengthen production capabilities. Management expects profit margins to remain strong, supported by favourable USD-INR realisations and an overall upward trend in pricing.
Historical Stock Returns for Cupid
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.81% | +5.64% | +47.16% | +95.16% | +783.40% | +1,644.08% |
How will the operationalization of the new Palava manufacturing facility impact Cupid Limited's production capacity and cost structure in the coming quarters?
What specific strategies is the company employing to capture market share in the consumer business to transition into a mainstream personal care brand?
How sustainable is the current pricing power, and what are the risks if USD-INR realizations fluctuate unfavorably?































